Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Condition:   Pharmacokinetics, Pharmacodynamics, Insulin Aspart Interventions:   Drug: I004;   Drug: NovoLog Sponsor:   Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Conditions:   Pharmacokinetics;   Pharmacodynamics Interventions:   Drug: I004;   Drug: NovoLog Sponsor:   Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Condition:   Pharmacokinetics, Pharmacodynamics, Insulin Aspart Interventions:   Drug: I004;   Drug: NovoLog Sponsor:   Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Conditions:   Pharmacokinetics;   Pharmacodynamics Interventions:   Drug: I004;   Drug: NovoLog Sponsor:   Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials

AT247, NovoLog ® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Condition:   Diabetes Mellitus, Type 1 Interventions:   Drug: AT247;   Drug: NovoLog;   Drug: Fiasp Sponsor:   Arecor Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2022 Category: Research Source Type: clinical trials